Page Not Found Error.
A page not found error occurred while processing your request.
Please return to home page.
Indication for Renvela and Renagel
Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients
Important Safety Information for Renvela and Renagel
- Sevelamer is contraindicated in patients with bowel obstruction.
- Caution should be exercised in patients with dysphagia, swallowing disorders, and
severe gastrointestinal (GI) motility disorders, including severe constipation or
major GI tract surgery.
- Common adverse events reported with sevelamer include vomiting, nausea, diarrhea,
dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include
pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and
- Uncommon cases of difficulty swallowing the Renagel (sevelamer hydrochloride) or Renvela® (sevelamer carbonate)
tablet have been reported. Caution should be exercised in these patients and consideration
given to using Renvela® (sevelamer carbonate) suspension in patients with a history
of difficulty swallowing.
- Drug-drug interactions may occur with some medications and should be taken into
consideration when instructing patients how to take sevelamer.
- Serum bicarbonate and chloride levels should be monitored.
- Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic
- Patients should be informed to take sevelamer with meals and to adhere to their
Please see full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.
The health information contained herein is provided for general education purposes only. Your healthcare professional is
the single best source of information regarding your health. Please consult your healthcare professional if you have any
questions about your health or treatment.